VacciZone
VacciZone is developing next generation antigen delivery and vaccine technologies for human and animal diseases based on its novel ASC technology. The company aims to change the vaccine and treatment development paradigm for preventable diseases by utilizing its patented platform that enhances antigen stability and efficacy, enabling vaccines to be sent at room temperature and improving global health solutions. It has recently advanced to animal testing stages for COVID-19 vaccines and holds multiple patents globally, including in the USA, Europe, China, and Japan. The company collaborates with Boğaziçi University and is working towards commercializing its innovative microencapsule technology, which can eliminate the need for cold chain storage and has potential for first-in-world applications in vaccine development.
Industries
Nr. of Employees
small (1-50)
VacciZone
Rumeli Hisarı Mah. Bebek Yolu Sok. Boğaziçi Üniversitesi Kuzey Kampüs Teknopark No:2/5, 202, Sarıyer-İstanbul
Products
SARS-CoV-2 vaccine candidate (protein-microparticle delivered recombinant spike fragments) — preclinical
A preclinical vaccine candidate that presents recombinant viral surface protein fragments on a protein microparticle carrier to enhance antigen presentation and thermostability.
Oncology vaccine candidate (tumor-antigen delivered on protein microparticles) — R&D/preclinical
A preclinical immunotherapy candidate that delivers tumor-associated antigen fragments on protein microparticles to stimulate anti-tumor immune responses.
Veterinary vaccine candidates using particulate delivery platform
Vaccine candidates for animal health that apply the same protein microparticle delivery platform to improve antigen stability and immune responses in veterinary use cases.
SARS-CoV-2 vaccine candidate (protein-microparticle delivered recombinant spike fragments) — preclinical
A preclinical vaccine candidate that presents recombinant viral surface protein fragments on a protein microparticle carrier to enhance antigen presentation and thermostability.
Oncology vaccine candidate (tumor-antigen delivered on protein microparticles) — R&D/preclinical
A preclinical immunotherapy candidate that delivers tumor-associated antigen fragments on protein microparticles to stimulate anti-tumor immune responses.
Veterinary vaccine candidates using particulate delivery platform
Vaccine candidates for animal health that apply the same protein microparticle delivery platform to improve antigen stability and immune responses in veterinary use cases.
Services
Licensing of a patented protein microparticle antigen-delivery platform and collaborative partnerships to support translation and productization.
On-site and collaborative preclinical services including cell-based antigen evaluation, immunogenicity monitoring, serological and neutralization assays (pseudovirus), and rodent studies including challenge testing in transgenic models.
Preparation of preclinical dossiers and procedural planning for first-in-human studies, including alignment with national regulator and ethics committee requirements.
Licensing of a patented protein microparticle antigen-delivery platform and collaborative partnerships to support translation and productization.
On-site and collaborative preclinical services including cell-based antigen evaluation, immunogenicity monitoring, serological and neutralization assays (pseudovirus), and rodent studies including challenge testing in transgenic models.
Preparation of preclinical dossiers and procedural planning for first-in-human studies, including alignment with national regulator and ethics committee requirements.
Expertise Areas
- Antigen delivery platform development
- Thermostable vaccine formulation
- Preclinical immunogenicity testing and animal models
- Recombinant protein antigen design and loading
Key Technologies
- Protein-based microparticle carriers
- Inflammasome-derived particulate adjuvants
- Recombinant protein antigens
- Thermostable formulation technologies
News & Updates
Prof. Nesrin Özören and team have made progress in cell experiments for coronavirus vaccine development using their microencapsulated technology, preparing for animal trials.
Vaccizone has licensed patents from Boğaziçi University for its innovative microencapsulated vaccine carrier technology, which can be used for developing vaccines that do not require cold chain storage.
Prof. Özören's team has developed a long-lasting vaccine technology that has been patented in multiple countries, including China, Japan, the US, and Europe.
Prof. Nesrin Özören and her team have secured patents for their durable vaccine carrier technology in China, Japan, the US, and Europe, marking a significant milestone in Turkish biotech innovation.
The team led by Prof. Nesrin Özören has developed a vaccine carrier that can keep antigens stable for 30 days at room temperature, potentially revolutionizing vaccine logistics.
First Turkish biotech patent in China for a vaccine carrier that can last 30 days at room temperature, applicable to various infectious diseases.
Prof. Nesrin Özören and team have made progress in cell experiments for coronavirus vaccine development using their microencapsulated technology, preparing for animal trials.
Vaccizone has licensed patents from Boğaziçi University for its innovative microencapsulated vaccine carrier technology, which can be used for developing vaccines that do not require cold chain storage.
Prof. Özören's team has developed a long-lasting vaccine technology that has been patented in multiple countries, including China, Japan, the US, and Europe.
Prof. Nesrin Özören and her team have secured patents for their durable vaccine carrier technology in China, Japan, the US, and Europe, marking a significant milestone in Turkish biotech innovation.
The team led by Prof. Nesrin Özören has developed a vaccine carrier that can keep antigens stable for 30 days at room temperature, potentially revolutionizing vaccine logistics.
First Turkish biotech patent in China for a vaccine carrier that can last 30 days at room temperature, applicable to various infectious diseases.